S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:ALNY

Alnylam Pharmaceuticals Earnings Date, Estimates, & History

$132.27
+2.91 (+2.25%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$129.22
$133.13
50-Day Range
$120.42
$169.29
52-Week Range
$117.58
$212.00
Volume
1.17 million shs
Average Volume
956,417 shs
Market Capitalization
$15.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.95

Earnings Summary

Upcoming
Earnings Date
Aug. 2Estimated
Actual EPS
(Apr. 28)
-$2.00 Missed By -$0.16
Consensus EPS
(Apr. 28)
-$1.84
Last Year's Q2 EPS
(4/28/2021)
-$1.71
Skip Charts & View Estimated and Actual Earnings Data

Alnylam Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Alnylam Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20223($1.86)($1.74)($1.79) 
Q2 20222($1.69)($1.64)($1.67) 
Q3 20222($1.66)($1.64)($1.65) 
Q4 20222($1.55)($1.54)($1.55) 
FY 20229($6.76)($6.56) ($6.65)

ALNY Earnings Information

Alnylam Pharmaceuticals last announced its quarterly earnings results on April 28th, 2022. The biopharmaceutical company reported ($2.00) EPS for the quarter, missing analysts' consensus estimates of ($1.84) by $0.16. The business had revenue of $186.90 million for the quarter, compared to the consensus estimate of $242.82 million. Its quarterly revenue was up 37.6% compared to the same quarter last year. Alnylam Pharmaceuticals has generated ($7.49) earnings per share over the last year (($7.49) diluted earnings per share). Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.78) to ($2.67) per share. Alnylam Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 2nd, 2022 based off prior year's report dates.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
8/2/2022
(Estimated)
        
4/28/20223/31/2022($1.84)($2.00)($0.16)$242.82 million$186.90 million      
2/10/2022Q4 2021($1.47)($2.16)($0.69)($2.16)$233.62 million$258.10 million    
10/27/20219/30/2021($1.51)($1.72)($0.21)($1.72)$218.69 million$187.63 million    
8/2/20216/30/2021($1.61)($1.61)($1.61)$193.66 million$220.55 million      
4/28/20213/31/2021($1.75)($1.71)+$0.04($1.71)$176.93 million$177.57 million  
2/10/202112/31/2020($1.76)($2.09)($0.33)($2.09)$142.49 million$163.56 million    
11/10/20209/30/2020($1.66)($2.18)($0.52)($2.18)$119.05 million$125.85 million    
8/6/20206/30/2020($1.82)($1.56)+$0.26($1.56)$98.76 million$77.50 million    
5/6/20203/31/2020($1.89)($1.62)+$0.27($1.62)$90.45 million$71.94 million  
2/6/2020Q4 2019($2.25)($2.47)($0.22)($2.47)$71.45 million$71.70 million  
10/31/2019Q3 19($2.17)($1.92)+$0.25($1.92)$57.14 million$70.06 million    
8/6/2019Q2 2019($2.06)($2.02)+$0.04($2.02)$42.24 million$38.20 million  
5/1/20193/31/2019($2.20)($1.73)+$0.47($1.73)$21.60 million$33.29 million
2/7/201912/31/2018($2.27)($2.09)+$0.18($2.09)$18.03 million$21.00 million  
11/7/20189/30/2018($2.02)($2.43)($0.41)($2.43)$22.66 million$2.07 million  
8/2/2018Q2 2018($1.74)($1.63)+$0.11($2.03)$16.96 million$29.91 million
5/3/2018Q1 2018($1.47)($1.41)+$0.06($1.41)$35.23 million$21.90 million
2/8/2018Q4 2017($1.38)($1.48)($0.10)($1.48)$19.31 million$37.90 million  
11/7/2017Q3 2017($1.23)($1.34)($0.11)($1.34)$28.15 million$17.10 million
8/9/2017Q2 2017($1.22)($1.34)($0.12)($1.34)$23.86 million$15.93 million  
5/5/2017Q1 2017($1.22)($1.25)($0.03)($1.25)$22.91 million$19.00 million
2/8/2017Q416($1.34)($1.32)+$0.02($1.32)$10.66 million$17.50 million  
11/2/2016Q316($1.14)($1.21)($0.07)($1.21)$9.14 million$13.70 million
8/4/2016Q216($1.24)($1.05)+$0.19($1.05)$8.09 million$8.70 million  
5/2/2016Q116($1.05)($1.21)($0.16)($1.21)$7.79 million$7.30 million  
2/11/2016Q415($0.96)($1.07)($0.11)($1.07)$9.59 million$7.60 million  
11/9/2015Q315($0.91)($0.91)($0.91)$7.55 million$6.30 million
8/6/2015Q215($0.75)($0.85)($0.10)($0.85)$12.64 million$8.69 million
5/7/2015Q115($0.65)($0.62)+$0.03($0.62)$15.40 million$18.51 million
2/12/2015Q414($0.66)($0.28)+$0.38($0.28)$13.10 million$24.00 million
11/5/2014Q314($0.63)($0.58)+$0.05($0.58)$8.93 million$11.00 million
8/7/2014Q214($0.54)($0.63)($0.09)($0.68)$9.36 million$7.30 million
5/8/2014Q114($1.18)($0.39)+$0.79$2.92$10.80 million$8.30 million
2/13/2014Q4 2013($0.48)($0.51)($0.03)($0.51)$9.98 million$10.80 million
11/6/2013Q3 2013($0.38)($0.48)($0.10)($0.48)$8.64 million$9.00 million  
8/8/2013Q2 2013($0.34)($0.29)+$0.05($0.29)$8.99 million$8.70 million  
5/6/2013Q1 2013($0.31)($0.15)+$0.16($0.15)$15.56 million$18.60 million  
2/7/2013Q4 2012($1.45)($1.20)+$0.25$15.82 million$8.50 million  
11/5/2012Q312($0.32)($0.31)+$0.01$17.30 million$16.80 million
8/6/2012($0.21)($0.25)($0.04)
5/3/2012($0.35)($0.25)+$0.10
2/9/2012($0.33)($0.33)  
11/1/2011($0.35)($0.31)+$0.04
8/1/2011($0.36)($0.33)+$0.03
5/2/2011($0.30)($0.38)($0.08)
2/17/2011($0.35)($0.16)+$0.19  
11/3/2010Q3 2010($0.39)($0.23)+$0.16($0.23)
8/4/2010Q2 2010($0.30)($0.35)($0.05)($0.35)
5/5/2010Q1 2010($0.30)($0.29)+$0.01($0.29)
2/25/2010Q4 2009($0.30)($0.19)+$0.11($0.19)
11/4/2009Q3 2009($0.24)($0.22)+$0.02($0.22)
8/6/2009Q2 2009($0.29)($0.55)($0.26)($0.55)
5/7/2009Q1 2009($0.24)($0.19)+$0.05($0.19)
2/24/2009Q4 2008($0.15)($0.23)($0.08)($0.23)
11/5/2008Q3 2008($0.21)($0.07)+$0.14($0.07)
8/6/2008Q2 2008($0.09)($0.31)($0.22)($0.31)
5/8/2008Q1 2008($0.14)($0.03)+$0.11($0.03)
2/7/2008Q4 2007($0.22)$0.04+$0.26$0.04
(Earnings results data provided by Zacks Investment Research)












Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings Frequently Asked Questions

When is Alnylam Pharmaceuticals's earnings date?

Alnylam Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 2nd, 2022 based off last year's report dates. Learn more on ALNY's earnings history.

Did Alnylam Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) missed the analysts' consensus estimate of ($1.84) by $0.16 with a reported earnings per share (EPS) of ($2.00). Learn more on analysts' earnings estimate vs. ALNY's actual earnings.

How can I listen to Alnylam Pharmaceuticals's earnings conference call?

The conference call for Alnylam Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Alnylam Pharmaceuticals's conference call transcript?

The conference call transcript for Alnylam Pharmaceuticals's latest earnings report can be read online. Read Transcript

How can I view Alnylam Pharmaceuticals's earnings report?

Alnylam Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Alnylam Pharmaceuticals generate each year?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded annual revenue of $844.29 million.

How much profit does Alnylam Pharmaceuticals generate each year?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a recorded net income of -$852.82 million. ALNY has generated -$7.49 earnings per share over the last four quarters.

What is Alnylam Pharmaceuticals's EPS forecast for next year?

Alnylam Pharmaceuticals's earnings are expected to grow from ($6.78) per share to ($2.67) per share in the next year.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.